

**NOTICE OF NEW HAMPSHIRE MEDICAID  
DRUG UTILIZATION REVIEW BOARD  
PUBLIC HEARING**

**June 22, 2010**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 3:00 p.m., on June 22, 2010 at the Chapel, Main Building, 105 Pleasant Street, State Office Park South, Concord, NH. A DUR meeting will immediately follow this public hearing.

The purpose of the public hearing on June 22, 2010, is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 3:00 p.m. and end no later than 4:00 p.m. The DUR meeting will begin at or before 4:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the June 22, 2010 public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

**DRUG UTILIZATION REVIEW BOARD MEETING**

**June 22, 2010**

**Meeting Agenda**

I. Old Business

- a. Minutes – 3/22/10 review

II. New Business

1. Overview of Drug Utilization Patterns for New Hampshire Medicaid
  - Prospective DUR Reports
  - Utilization Reports
  - Retrospective DUR Reports
  
2. Review of Proposed Preferred Drug List Therapeutic Classes
  - Antiviral for Treatment/Prophylaxis of Influenza
  - Androgen Hormone Inhibitors
  - Topical Antivirals (Legend)
  - Topical Antibiotics (Legend)
  - Tramadol & Tramadol-like Derivatives
  - Dipeptidyl Peptidase-4 Inhibitors and Combination
  - Topical Analgesics and Anesthetics (Legend)
  
3. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
  - Growth Hormone
  - Oxycontin®
  - Receptor-Selective NSAID Medications
  - Proton Pump Inhibitors

4. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes
  - Fibromyalgia

#### IV. Adjourn

Further information regarding the agenda items may be obtained after June 8, 2010, by contacting Robin Calley, at 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: [rlcalley@dhhs.state.nh.us](mailto:rlcalley@dhhs.state.nh.us).

Notice of intent to testify at the June 22, 2010 public hearing, and/or submittal of written comments, should be directed to Robin Calley, Office of Medicaid Business and Policy, 129 Pleasant Street, Concord, NH, 03301, 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: [rlcalley@dhhs.state.nh.us](mailto:rlcalley@dhhs.state.nh.us).